A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

Kathrin Schwager1, Alessandra Villa1, Christoph Rösli2, Dario Neri2, Maria Rösli-Khabas3 and Gerhard Moser3*

Abstract

Background: The antibody-based targeted delivery of bioactive molecules to tumour vasculature is an attractive avenue to concentrate therapeutic agents at cancer sites, while sparing normal organs. L19, F8 and F16 are three fully human monoclonal antibodies, specific to splice isoforms of fibronectin and tenascin-C, which bind to sites of active tissue remodeling and which are currently in Phase I and II clinical trials as radio-immunoconjugates and immunocytokines in patients with cancer and arthritis.

In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions.

Methods: We performed a comparative immunofluorescence analysis with the L19, F8 and F16 antibodies in 40 freshly frozen human head and neck cancer specimens.

Results: On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. Interestingly, some specimens exhibited striking differences in staining by the three antibodies.

Conclusions: These results suggests that an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may represent the most logical avenue for offering the best possible antibody to any given patient.

Background

Antibody-based anti-cancer pharmacodelivery strategies critically rely on the availability of good-quality tumour markers, allowing a clear differentiation between diseased tissue and healthy organs. Markers of the tumour neovasculature are particularly attractive, because of the dependence of tumours on new blood vessels to sustain growth and invasion, and because of the accessibility of these structures from the bloodstream. Furthermore, angiogenesis is a common feature of virtually all malignancies [1,2].

The alternatively spliced extra domain A (EDA) and B (EDB) of fibronectin and A1 domain of tenascin-C represent three of the best-characterized markers of angiogenesis and have been reported to be expressed around the neo-vasculature and in the stroma of virtually all types of aggressive solid tumours. Three human monoclonal antibodies specific to these targets have been developed by our groups and moved to clinical trials: L19 (specific to EDB) [3], F8 (specific to EDA) [4] and F16 (specific to the A1 domain of tenascin-C) [5]. Several antibody derivatives, based on the modification of L19, F8 or F16 with cytokines or iodine radionuclides, are currently investigated in Phase I and Phase II clinical trials in patients with cancer and with rheumatoid arthritis [6,7]. These biopharmaceuticals are called L19-124I, L19-131I, L19-IL2, L19-TNF, F8-IL10, F16-124I, F16-131I, F16-IL2, indicating the modular nature of these derivatives, in which the antibody moiety is used to deliver a payload at the site of disease.

The staining patterns of the L19 and F16 antibody in head and neck tumours [5,8] have previously been published by our group in separate articles, but the relative staining intensities of the two antibodies have so far not been compared. Furthermore, a radioiodinated version of the L19 antibody has been tested in scFv format in a
small immunoscintigraphic clinical study in patients with head and neck squamous cell carcinomas (SCC), observing tumour localization in 4 of 5 patients [9]. More recently, radiiodinated derivatives of both L19 and F16 antibodies in SIP format [5,10] have been studied in Phase II clinical trials in over 100 patients with cancer, including head and neck cancer patients [6] [unpublished results].

In this article, we report the first comparative analysis of expression patterns for the extra domains EDB and EDA of fibronectin and A1 of tenascin-C in both primary and metastatic head and neck cancer lesions.

Methods

Specimens

A total of 40 freshly frozen OCT embedded tissue samples were obtained from the University Hospital of Salzburg (Austria), Department of ear-nose-throat diseases. This study was examined by the ethical committee of the province Salzburg and patient consents for the tissue collection were obtained prior to surgery. The specimens were collected during major head and neck tumour operations (table 1). The tissues were stored at -80°C. Sections of 10 μm were cut.

Immunofluorescence staining

The L19 antibody, specific to the extra domain B (EDB) of fibronectin, the F8 antibody, specific to the extra domain A (EDA) of fibronectin, and the F16 antibody, specific to the extra domain A1 of tenascin-C, have been described before [3-5]. All antibodies were isolated from ETH2 antibody libraries, affinity matured, had dissociation constants in the low nanomolar range and exhibited kinetic dissociation constants k_{off} towards the respective antigens <10^{-2} s^{-1} in real-time interaction analysis experiments on a BiACore 3000 instrument (GE Healthcare, Zurich, Switzerland). As a negative control the antibody KSF was used. KSF is specific to hen egg lysozyme and does not show any specificity towards human antigens. All antibodies were biotinylated and carried a comparable number of biotin molecules.

For immunofluorescence, a double staining for EDA, EDB resp. TnC-A1 and von Willebrand factor was performed. The following primary antibodies were used: biotinylated F8, L19, F16 and KSF (negative control antibody) in small immunoprotein format (SIP) (2 μg/ml for all four antibodies) and polyclonal rabbit anti-human von Willebrand factor (Dako, Glostrup, Denmark). For detection of the biotinylated SIPs Streptavidin Alexa Fluar 488 (Invitrogen, Basel, Switzerland) was used. As secondary detection antibody for the anti-von Willebrand factor antibody Alexa Fluar 488 goat anti-rabbit (Invitrogen, Basel, Switzerland) antibody was used.

Cryosections were fixed in chilled aceton, rehydrated in PBS (100 mM NaCl, 30 mM Na_2HPO_4, 20 mM NaH_2PO_4, pH 7.4) and blocked with 20% goat serum in PBS. Primary antibodies were added in a final concentration of 2 μg/ml in 3% bovine serum albumin (BSA)/PBS solution and incubated for 1 h. After washing in PBS secondary antibodies were added in 3% bovine serum albumin (BSA)/PBS solution and incubated for 1 h. Sections were washed in PBS and mounted with fluorescent mounting medium (Dako, Glostrup, Denmark) and analyzed with a confocal laser scanning microscope (LSM 510 META, Zeiss, Oberkochen, Germany). Microscopic exposure times were identical for all antibodies. Images were further processed using the Imagej software http://rspb.info.nih.gov/ji.

Semi-quantitative evaluation of results

Staining intensities of the extra domains A and B of fibronectin and the A1 domain of tenascin C were independently assessed by experienced investigators. Staining was scored using 7 scores: 0, 0.5, 1, 1.5, 2, 2.5 and 3, according to a training table, representing a selection of the corresponding staining intensities as reference. Data are expressed as the mean ± standard error of the mean.

Results and Discussion

The staining intensities of biotinylated derivatives of the L19, F8 and F16 antibodies in 40 frozen specimens of head and neck cancer were studied by three-colour immunofluorescence microscopy. The tissue series included tumours of the oral cavity, the pharynx and the larynx [table 1]. Primary benign lesions, malignant tumours as well as metastatic cancer specimens were analyzed. The three antibodies L19, F8 and F16 had comparable high affinities towards their cognate antigen and were used in identical concentrations. The KSF antibody, specific to hen egg lysozyme and with no known reactivity towards human antigens [11], was used as negative control (data not shown). Figure 1 shows representative immunofluorescence findings with the three antibodies (green) in different tumour sections. Cell nuclei were stained with DAPI (blue), while blood vessels were coloured in red using an anti-von Willebrand antibody. In most specimens, all three antibodies exhibited a diffuse stromal staining, similar to previously described patterns of fibronectin and tenascin-C expression [12,13]. Interestingly, some specimens exhibited striking differences in staining by the three antibodies [Figure 1]. This observation suggests that, while at least one of the three antibodies is generally capable of intensely staining a given tumour, an individualized treatment procedure (e.g., choice of L19, F8 or F16 based on immuno-PET or immunofluorescence procedure) may
represent the most logical avenue for offering the best possible antibody to any given patient.

Figure 2 presents a semi-quantitative analysis of staining intensities of L19, F8 and F16, ranging from 0 (absent), to 3 (+++). Independent investigators assessed all pictures, assigning a scoring intensity to each specimen. The average of these values and the corresponding standard error were displayed in the figure. Primary tumours and metastatic tumour lesions as well as primary benign and malign tumours were analyzed, as well as tumour samples from different anatomical locations (oral cavity, larynx and pharynx). On average, F8 and F16 exhibited similar staining intensities, which were typically stronger than L19. As a consequence, armed antibodies based on F8 or F16 may represent the best choice for the treatment of head and neck cancer.

Table 1 Description of samples used for the immunofluorescence analysis

| Sample No. | Primary tumor/ LN metastasis | Tissue origin | Histological result |
|------------|-----------------------------|---------------|---------------------|
| 1          | tumour                      | parotid gland | PA                  |
| 2          | metastasis                  | lymph node   | SCC                 |
| 3          | tumour                      | hypopharynx  | SCC                 |
| 4          | tumour                      | hypopharynx  | SCC                 |
| 5          | tumour                      | uvula        | SCC                 |
| 6          | tumour                      | skin (left auricle) | BCC |
| 7          | metastasis                  | lymph node   | SCC                 |
| 8          | tumour                      | hypopharynx  | SCC                 |
| 9          | metastasis (from 8)         | lymph node   | SCC                 |
| 10         | metastasis                  | lymph node   | SCC                 |
| 11         | tumour                      | skin (nose)  | SCC                 |
| 12         | tumour                      | hypopharynx  | SCC                 |
| 13         | tumour                      | oral cavity (tongue) | SCC |
| 14         | metastasis (from 13)        | lymph node   | SCC                 |
| 15         | metastasis (from 8)         | lymph node   | SCC                 |
| 16         | tumour                      | parotid gland | PA                |
| 17         | tumour                      | oropharynx   | SCC                 |
| 18         | tumour                      | oropharynx   | SCC                 |
| 19         | tumour                      | parotid gland | PA                |
| 20         | tumour                      | parotid gland | PA                |
| 21         | tumour                      | hypopharynx  | SCC                 |
| 22         | tumour                      | larynx (vocal cord) | SCC |
| 23         | tumour                      | larynx       | SCC                 |
| 24         | tumour                      | larynx       | SCC                 |
| 25         | metastasis                  | lymph node   | CS                  |
| 26         | tumour                      | oropharynx (tonsil) | SCC |
| 27         | tumour                      | larynx       | SCC                 |
| 28         | tumour                      | oropharynx   | SCC                 |
| 29         | tumour                      | supraglottis | SCC                 |
| 30         | tumour                      | supraglottis | SCC                 |
| 31         | tumour                      | supraglottis | SCC                 |
| 32         | tumour                      | oral cavity (lower jaw - alveolar crest) | SCC |
| 33         | tumour                      | larynx (glottis - posterior commissure) | SCC |
| 34         | tumour                      | oral cavity (palatal arch) | SCC |
| 35         | tumour                      | nasopharynx  | SCC                 |
| 36         | metastasis                  | lymph node   | PDTC                |
| 37         | metastasis                  | lymph node   | SCC                 |
| 38         | tumour                      | oropharynx (vallecula epiglottica) | SCC |
| 39         | tumour                      | larynx (epiglottis) | SCC |
| 40         | tumour                      | larynx (epiglottis) | SCC |

1 Indication of primary tumour sample (LN: cervical lymph node). 2 Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma (benign); CS: carcinosarcoma; PDTC: poorly differentiated thyroid carcinoma; BCC: basal cell carcinoma. 3 Status post radiotherapy.
Figure 1 Immunofluorescence staining of head and neck cancer samples. The expression patterns and intensities of the splice isoforms extra domain A (EDA) and extradomain B (EDB) of fibronectin and the A1 domain of tenascin C were detected with the antibodies F8, L19 and F16, respectively (shown in green). A co-staining with an anti-von Willebrand factor antibody that stains blood vessels (red) and Dapi (blue) was performed. Abbreviations: SCC: squamous cell carcinoma; PA: pleomorphic adenoma.
whereas L19 may be more appropriate for other cancer types which strongly express the EDB domain of fibronectin (e.g., kidney cancer; [7]). However, it cannot be excluded that the weaker staining observed for EDB may be a consequence of lower stability of this antigen, which has been reported in case of tissue section storage at -80°C for longer than 20 days [14]. In a previous study, a radioiodinated version of the L19 antibody has been tested in scFv format in a small immunoscintigraphic clinical study in patients with head and neck squamous cell carcinomas. Successful targeting of the primary tumour could be achieved in 4 out of 5 patients [9]. Further imaging studies are needed to reveal whether targeting of F16 and F8 is superior to L19 in head and neck cancer patients. Indeed, two Phase II clinical trials with SIP(L19) [6] and SIP(F16) labelled with 124I [15] are currently being performed.

Conclusions
The majority of head and neck cancer types exhibited a diffuse pattern of expression for splice isoforms of fibronectin and of tenascin-C. The clinical stage antibodies F8 and F16 stained tumours more intensely compared to L19 and may thus represent the most suitable candidates to be used as vehicles for pharmacodelivery applications.

Acknowledgements
Financial support from the ETH Zurich, the Swiss National Science Foundation (grant # 310030_126908) and European Union Projects IMMUNO-PDT (grant # LSHC-CT-2006-037489) and ADAMANT (HEALTH-FP7-2008-201342) is gratefully acknowledged.

Author details
1Philochem AG, c/o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Str. 10 HCI E520, CH-8093 Zurich, Switzerland. 2Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland. 3Department of Otorhinolaryngology, Paracelsus Medical University, Federal Hospital Salzburg, Muller-Hauptstrasse 48, A-5020 Salzburg, Austria.

KS performed the immunofluorescence stainings, evaluated the results and assisted in preparing the manuscript. DN proposed, designed, and supervised the project, and wrote and revised the manuscript. CR performed the microscopical analysis, evaluated the results and revised the manuscript.

Figure 2 Analysis of staining intensities. Comparison of staining intensities obtained with the antibodies F8, L19 and F16 in A) primary tumours and metastasis tumour samples and in B) primary benign and primary malignant tumour specimens. C) Average staining intensities of tumours of the oral cavity, the pharynx or the larynx. Standard Errors of the Mean of scoring values are displayed.
GM designed the project, performed the surgery together with MRK, and wrote and revised the manuscript. All authors read and approved the final manuscript.

Competing interests
DN is the founder and shareholder of Philogen S.p.A. (Siena, Italy), the company that owns the F8, L19 and F16 antibodies.

Received: 21 March 2011 Accepted: 8 May 2011 Published: 8 May 2011

References
1. Schliemann C, Neri D: Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007, 1776:175-192.
2. Schrama D, Reisfeld RA, Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006, 5:147-159.
3. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273:21769-21776.
4. Villa A, Trachsel E, Kaipar M, Schliemann C, Sommavilla R, Rybak JS, Rosli C, Borsi L, Neri D: A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008, 122:2405-2413.
5. Brack SS, Silacci M, Birchler M, Neri D: Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006, 12:3200-3208.
6. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganeli G, Mariani G, et al: Expression of the oncofetal ED-B containing fibronectin isoform in hematologic tumors enables ED-B targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113(10):2265-74.
7. Johannsen M, Spitalel C, Cugnoli G, Roigas J, Weikert S, Kempensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, et al: The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010, 46:2926-2935.
8. Birchler MT, Milisavljevic D, Pfalz M, Neri D, Odermatt B, Schmid S, Stoeckli SJ: Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003, 113:1231-1237.
9. Birchler MT, Thuerl C, Schmid D, Neri D, Wabbel R, Schubiger A, Stoeckli SJ, Schmid S, Goerres GW: Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenic antibody fragment. Otolaryngol Head Neck Surg 2007, 136:543-548.
10. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, Zardi L: Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102:75-85.
11. Frey K, Zivanovic A, Schwager K, Neri D: Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb) 2011, 3(4):468-78.
12. Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S: Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 2009, 64:28-33.
13. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D: Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 2009, 33:1718-1722.
14. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemani G, Zardi L: Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994, 59:11-16.
15. Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW, Dinkelborg LM, Leemans CR, Neri D, van Dongen GA: (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 2009, 36:1235-1244.